Efficacy of Daclizumab HYP Treatment in Patients with Highly Active Relapsing-Remitting Multiple Sclerosis: Results from the SELECT Study

被引：0
|
作者：
Mehta, Lahar [1 ]
Giovannoni, Gavin [2 ]
Radue, Ernst-Wilhelm [3 ]
Havrdova, Eva [4 ]
Riester, Katherine [5 ]
Greenberg, Steven [6 ]
Elkins, Jacob [5 ]
机构：
[1] Biogen Idec Inc, Cambridge, MA USA
[2] Queen Mary Univ London, London, England
[3] Med Imaging Anal Ctr, Basel, Switzerland
[4] Fac Hosp Neurol Praha, Prague, Czech Republic
[5] Biogen Idec Inc, Cambridge, MA USA
[6] Abbott Biotherapeut, Redwood City, CA USA
来源：
NEUROLOGY | 2013年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P07113
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Effect of daclizumab HYP treatment in highly active relapsing-remitting multiple sclerosis: results from the SELECT study
    Giovannoni, G.
    Radue, E. W.
    Havrdova, E.
    Riester, K.
    Greenberg, S.
    Glyman, S.
    Elkins, J.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 189 - 189
  • [2] Efficacy of daclizumab HYP across subgroups of varying relapsing-remitting multiple sclerosis disease severity: results from the SELECT study
    Giovannoni, G.
    Greenberg, S.
    Tsao, C.
    Elkins, J.
    Riester, K.
    Gold, R.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 131 - 131
  • [3] Daclizumab HYP efficacy on disease outcome measures using an expanded definition of highly active relapsing-remitting multiple sclerosis: results from SELECT and DECIDE
    Giovannoni, G.
    Ziemssen, T.
    Ma, W.
    Fam, S.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 663 - 663
  • [4] Daclizumab HYP efficacy on disease outcome measures using an expanded definition of highly active relapsing-remitting multiple sclerosis: Results from SELECT and DECIDE
    Giovannoni, Gavin
    Ziemssen, Tjalf
    Ma, Wei
    Fam, Sami
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (01) : 154 - 155
  • [5] Efficacy of daclizumab HYP across subgroups of varying relapsing-remitting multiple sclerosis disease severity: results from the SELECT study
    Giovannoni, G.
    Greenberg, S.
    Tsao, C.
    Elkins, J.
    Riester, K.
    Gold, R.
    [J]. JOURNAL OF NEUROLOGY, 2014, 261 : S94 - S94
  • [6] Safety and tolerability of daclizumab HYP treatment in relapsing-remitting multiple sclerosis: results of the DECIDE study
    Selmaj, K.
    Kappos, L.
    Arnold, D. L.
    Havrdova, E.
    Boyko, A.
    Kaufman, M.
    Wiendl, H.
    Rose, J.
    Greenberg, S.
    Demirhan, E.
    Riester, K.
    Sweetser, M.
    Elkins, J.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 109 - 109
  • [7] The Safety and Efficacy of Daclizumab HYP in Relapsing-Remitting Multiple Sclerosis in the SELECTION Extension Study: Primary Results
    Giovannoni, Gavin
    Gold, Ralf
    Selmaj, Krzysztof
    Havrdova, Eva
    Montalban, Xavier
    Radue, Ernst-Wilhelm
    Stefoski, Dusan
    McNeill, Manjit
    Rana, Jitesh
    Elkins, Jacob
    O'Neill, Gilmore
    [J]. NEUROLOGY, 2013, 80
  • [8] Daclizumab for the treatment of relapsing-remitting multiple sclerosis
    Herwerth, Marina
    Hemmer, Bernhard
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (06) : 747 - 753
  • [9] Efficacy and safety of daclizumab high-yield process (DAC HYP) treatment in relapsing-remitting multiple sclerosis: results from the SELECTION extension study
    Giovannoni, G.
    Gold, R.
    Selmaj, K.
    Havrdova, E.
    Montalban, X.
    Radue, E. -W.
    Stefoski, D.
    McNeill, M.
    Rana, J.
    Elkins, J.
    O'Neill, G.
    [J]. JOURNAL OF NEUROLOGY, 2013, 260 : S50 - S51
  • [10] Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis
    Derfuss, T.
    Bergvall, N. K.
    Sfikas, N.
    Tomic, D. L.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (09) : 1687 - 1691
12345